- Home
- YMAT vs MRKR Comparison
YMAT vs MRKR Comparison
Compare YMAT & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YMAT | MRKR |
|---|---|---|
| Founded | 1970 | N/A |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3M | 16.6M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | YMAT | MRKR |
|---|---|---|
| Price | $0.80 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.25 |
| AVG Volume (30 Days) | 196.1K | ★ 303.8K |
| Earning Date | 04-29-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $17,563,985.00 | $4,694,988.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.65 | $0.81 |
| 52 Week High | $6.45 | $5.95 |
Technical Indicators
Market Signals| Indicator | YMAT | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 63.78 |
| Support Level | N/A | $1.15 |
| Resistance Level | N/A | $1.27 |
| Average True Range (ATR) | 0.00 | 0.11 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 77.11 |
Price Performance
Historical ComparisonAbout YMAT J-Star Holding Co. Ltd. Ordinary Shares
J Star Holding Co Ltd is engaged in the research, development and manufacturing of carbon fiber for a wide variety of products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.